In chapter 2, it was demonstrated that in 2016 several second-generation ribavirin-free DAA regimens achieved viral eradication in ≥95% in different type of patients other than those with prior NS5A-inhibitor exposure or decompensated cirrhosis. In chapter 3, various patient-reported outcomes (PROs) were prospectively evaluated before, during and after DAA treatment. Ribavirin use was the only independent predictor of the transient decline in the mental health-related quality of life (HRQL) that occurred at the end of treatment (EOT). Twelve weeks after the end of treatment (FU12), the HRQL had not changed compared to the baseline-levels. Through the REACH-project, described in chapter 4, 42 lost to follow-up (LFU) chronic HCV patients were re-evaluated by means of screening positive HCV diagnostics from the past 15 years. Retrieval was most feasible regionally since 28.3% of the patients eligible for retrieval from the Utrecht province were traced compared to 7.7% of those patients living outside the region. In 24% of the reevaluated patients, the liver fibrosis had progressed to an advanced stage (Metavir F3-F4). At follow-up, 59% of the traced patients had scheduled or initiated DAA therapy. Chapter 5 covers retrieval of chronic hepatitis B virus (HBV) patients. General practitioners (GPs) in Utrecht were asked to trace LFU chronic HBV patients and 49% returned a response that included either reevaluation outcomes or updated information on the patient’s follow-up status. Finally, 10% (N=62) of the eligible LFU chronic HBV patients was reevaluated of which 32% (N=20) was referred to a hospital. Reasons for previous loss to follow-up were explored in retrieved chronic HCV patients through in-depth interviews, characterized in chapter 6. A grounded theory based qualitative analysis uncovered ‘maintaining the achieved balance’ as the basic socio-psychological process in LFU HCV patients. The balance is steadfast state of mind in which patients marginalize having HCV. Patients arrived at this balance through a ...